Precigen (STU:I5X) ROCE %: -17.15% (As of Mar. 2026)


STU:I5X Precigen Inc STU:I5X
62 GF Score
Price €4.92
GF Value €5.31
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Precigen ROCE %?

Precigen STU:I5X -5.38% 62 ROCE % is -17.15% as of Mar. 2026. GuruFocus rates STU:I5X with a GF Score™ of 62/100 and a GF Value™ of €5.31 (Fairly Valued). The stock has 10 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Precigen's annualized ROCE % for the quarter that ended in Mar. 2026 was -17.15%.

Precigen  (STU:I5X) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Precigen ROCE % Related Terms

Precigen ROCE % Historical Data

* Premium members only.

The historical data trend for Precigen's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Precigen ROCE % Chart

Precigen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -31.89 -33.10 -71.18 -103.78 -192.35

Precigen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -186.28 -111.86 -530.61 -63.92 -17.15
STU:I5X
62GF Score
Precigen Inc STU:I5X
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Precigen ROCE % Calculation

Precigen's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-210.743/( ( (138.729 - 20.55) + (132.801 - 31.859) )/ 2 )
=-210.743/( (118.179+100.942)/ 2 )
=-210.743/109.5605
=-192.35 %

Precigen's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-17.372/( ( (132.801 - 31.859) + (119.912 - 18.255) )/ 2 )
=-17.372/( ( 100.942 + 101.657 )/ 2 )
=-17.372/101.2995
=-17.15 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -17.15% mean?
Precigen (STU:I5X) has a ROCE % of -17.15% as of Mar. 2026.
Is Precigen's ROCE % too high?
Precigen's current ROCE % is -17.15%. Overall, Precigen has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Precigen's ROCE % compare to KARD and SLBT?
Precigen's ROCE % of -17.15% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Precigen's current ROCE % is -17.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precigen stock overvalued right now?
Based on GuruFocus' analysis, Precigen (STU:I5X) is currently considered Fairly Valued. The stock's GF Value™ is €5.31, compared to a current price of €4.92 — trading 7.3% below its estimated fair value. The current ROCE % is -17.15%. Precigen's overall GF Score™ is 62/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Precigen (STU:I5X), the current ROCE % is -17.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Precigen (STU:I5X) Overvalued in 2026?

Based on GuruFocus' analysis, Precigen stock appears to be undervalued. The current stock price of €4.92 is trading 7.3% below its estimated GF Value™ of €5.31. GuruFocus considers Precigen to be Fairly Valued.

Key valuation signals for STU:I5X:

  • ROCE %: -17.15%
  • GF Value™: €5.31 vs. price of €4.92 (7.3% below fair value)
  • GF Score™: 62/100 with 10 warning signs

No single metric tells the full story. See the STU:I5X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precigen Business Description

Other Exchanges PGEN:USA
Address 20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
62GF Score

Get the complete analysis for STU:I5X

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.92
Price
€5.31
GF Value